Novo Nordisk considers another facility; Lonza’s new CEO shares his priorities

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

Novo Nordisk has secured land …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Zenas BioPharma and BMS enter antibody development deal

BMS will obtain exclusive rights for the development and marketing of obexelimab in licensed regions. Credit: Stock-Asso / Shutterstock.com. Zenas BioPharma and Bristol Myers Squibb

September 6, 2023

Silo Pharma Secures Exclusive Global License for Alzheimer’s Therapeutic | Psychedelic Invest

SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing

July 16, 2024

Updated atrial fibrillation guidelines focus on risk management and patient-centered care

The 2024 ESC Guidelines for the management of atrial fibrillation, developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS), contain a number of

August 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.